[Chemotherapy of gastric cancer patients with hepatic metastases].
The effect of post-operative adjuvant chemotherapy on the prognosis of gastric cancer patients with hepatic metastases was evaluated. Forty-two cases were classified into-following four groups: (A) no chemotherapy, (B) short-term chemotherapy (5 g of 5 FU i.v., or 1/2 FM (F') C alone), (C) long-term chemotherapy (1/2 MF (F') C plus 0.6 g of FT-207 per os), (D) long-term chemotherapy (1/2 MF (F') C plus 1.5 g/day of FT-207 per annum). Six, nine, twelve month survival rates of patients in group (D) was significantly higher than group (A). Mean survival time of each group was: (A) 4.7, (B) 5.2, (C) 5.7 and (D) 9.1 months. Correlation between the survival time and the total dose of FT-207 was observed. Total dose of FT-207 in group (D) was 129.3 g and 60.8 g in group (C). These may reflect the results that the rectal administration was more effective than the oral administration of FT-207.
D000284:Administration, Oral; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D011379:Prognosis; D013274:Stomach Neoplasms / Q000601:surgery; D013488:Suppositories; D005641:Tegafur / Q000008:administration & dosage*
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D013488:Suppositories; D005641:Tegafur; D016685:Mitomycin; D005472:Fluorouracil